AC Immune's Alzheimer's Vaccine Candidate Elicit Response In Early-Stage Study; Shares Rally

  • AC Immune SA (NASDAQ: ACIU) soars in premarket on robust volume, on the heels of positive interim results from its ongoing Phase 1b/2a trial evaluating its anti-phospho-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer's disease.
  • ACI-35.030 is under development in collaboration with Johnson & Johnson's JNJ Janssen Pharmaceuticals under a 2014 agreement.
  • Data shows that after the first injection of ACI-35.030, both lowest and second highest dosages, 100% of the patients demonstrated a potent antigen-specific antibody response against pTau, achieving antibody levels much higher than pre-vaccination levels. It does not show clinically relevant adverse events.
  • The company says that anti-pTau vaccination generates antibody responses with pharmacokinetic characteristics and target epitopes that differ substantially from the company's anti-Tau monoclonal antibody semorinemab.
  • The third and highest dosing group, per the study protocol, is up next.
  • The 32-subject trial's primary objective is to assess the safety, tolerability, and immunogenicity of different doses of ACI-35.030 over a 48-week in patients with early AD. Other endpoints will assess clinical and cognitive parameters as well as additional immunogenicity and safety parameters.
  • Price Action: ACIU gained 117.7% at $15.87 in premarket trading on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsSmall CapFDATop StoriesGeneralAlzheimer’sJanssen PharmaceuticalsPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!